BioNTech (NASDAQ:BNTX) Posts Quarterly Earnings Results, Beats Estimates By $0.18 EPS

BioNTech (NASDAQ:BNTX) released its earnings results on Tuesday. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.18, FiscalAI reports. BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The business had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $941.99 million. During the same period last year, the business earned $1.08 earnings per share. The firm’s revenue was down 23.7% on a year-over-year basis.

Here are the key takeaways from BioNTech’s conference call:

• BioNTech beat its raised 2025 revenue guidance and finished the year with a strong liquidity position of EUR 17.2 billion, enabling continued investment in late‑stage oncology programs.
• Management highlighted rapid late‑stage progress for its oncology backbone pumitamab — >4,000 patients enrolled, multiple global phase 3 trials with BMS underway, and several event‑driven readouts expected in 2026 that could be material value inflection points.
• Several ADC programs showed promising monotherapy data (notably BNT324 with pan‑tumor activity and a favorable safety profile), and the company plans pivotal pumitamab+ADC combinations and a phase 3 in first‑line mCRPC imminently.
• BioNTech expects lower Comirnaty/COVID‑19 vaccine revenues in 2026 and provided guidance of EUR 2.0–2.3 billion total revenue, citing a competitive U.S. market, contract transitions in Europe, and direct‑sales impacts in Germany.
• Founders Ugur Sahin and Özlem Türeci will form a new independent next‑generation mRNA company (BioNTech to contribute certain rights/technologies and hold a minority stake); a binding agreement is expected by mid‑2026 and the founders will transition by end‑2026, creating strategic uncertainty around long‑term leadership.

BioNTech Stock Performance

Shares of BNTX stock opened at $83.89 on Wednesday. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00. The company has a market capitalization of $18.89 billion, a price-to-earnings ratio of -31.90 and a beta of 1.51. The company has a 50-day simple moving average of $106.73 and a 200 day simple moving average of $102.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.12.

Key BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Quarterly results beat on the headline EPS and revenue metrics, and management highlighted a strong cash position (~€17.2B) plus a pipeline with multiple late‑stage readouts slated this year — supports medium/long‑term R&D execution. Q4 & Corporate Update
• Positive Sentiment: Company reported Q4 revenue and EPS that topped some expectations (revenue ~$1.06B; EPS -$0.39 vs consensus -$0.57), showing operational resilience despite YoY revenue declines. Earnings Summary
• Neutral Sentiment: Analyst reaction mixed — Jefferies trimmed its price target (from $151 to $138) but kept a Buy rating, indicating continued analyst confidence on longer-term upside despite near-term risks. PT / Analyst Note
• Negative Sentiment: Cofounders Ugur Sahin and Özlem Türeci announced they will leave by end‑of‑2026 to form an independent mRNA company; BioNTech will contribute related rights/tech in exchange for a minority stake — market concern: leadership transition plus potential technology transfer raises strategic and execution risk. Founders Leaving (Reuters)
• Negative Sentiment: FY‑2026 guidance came in below street expectations (company guided ~€2.0–2.3B vs analyst consensus ~\$3.1B), signaling near‑term revenue growth pressure and driving downward revisions to near‑term earnings outlook. Guidance & Financials
• Negative Sentiment: Immediate market reaction: headlines and social coverage tied the founders’ exit and the weaker outlook to a sharp share selloff; several outlets reported double‑digit declines in the stock. Market Reaction / Blockonomi Market Reaction / Tokenist
• Negative Sentiment: Heightened legal risk: a plaintiff‑side firm (Johnson Fistel) is soliciting shareholders to inquire about potential claims tied to executive actions — could increase investor litigation risk and distraction. Johnson Fistel Notice

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Morgan Stanley reiterated an “overweight” rating on shares of BioNTech in a research note on Tuesday. Raymond James Financial reaffirmed an “outperform” rating on shares of BioNTech in a report on Tuesday. Bank of America reiterated a “buy” rating and issued a $128.00 target price on shares of BioNTech in a research note on Tuesday. Leerink Partners cut BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price target for the company. in a report on Monday, February 2nd. Finally, Berenberg Bank reissued a “buy” rating on shares of BioNTech in a research report on Friday, January 23rd. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BioNTech has an average rating of “Moderate Buy” and an average target price of $136.00.

Institutional Investors Weigh In On BioNTech

Hedge funds have recently bought and sold shares of the stock. Alberta Investment Management Corp bought a new position in shares of BioNTech during the fourth quarter worth approximately $1,021,000. ADAR1 Capital Management LLC bought a new stake in BioNTech in the 3rd quarter valued at $986,000. Quantessence Capital LLC acquired a new position in BioNTech in the 3rd quarter valued at $955,000. Brevan Howard Capital Management LP acquired a new position in BioNTech in the 3rd quarter valued at $697,000. Finally, Virtus Investment Advisers LLC increased its position in BioNTech by 70.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 7,207 shares of the company’s stock worth $686,000 after buying an additional 2,971 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.